Type of information: Plant acquisition
Acquired company: Galderma R&D site in Sophia-Antipolis - Nestlé Skin Health (Switzerland)
Acquiring company: Nuvisan (Germany)
- • On August 31, 2018, the Nuvisan group, one of Europe´s leading CRO´s focused on early stage drug development for
the life science industry, signed an agreement with Nestlé Skin Health/ Galderma to take over parts of the R&D capacities in Sophia-Antipolis, France. Nuvisan intends to start its operations in Sophia Antipolis in October 2018. With these new capacities, NUVISAN expertise will be extended to the fields of chemistry, liquid and semi-solid
formulation development whilst creating an operational hub in close proximity to Southern European customers.
- The Galderma R&D site in Sophia-Antipolis which opened in 2006 is the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities will strengthen Nuvisan’s core service lines in Bioanalysis, Clinical Trial Supplies and Pharmaceutical Analytics as well as enhancing the portfolio by adding GMP-API synthesis and formulation capability for prescription drugs and
- Nuvisan thus underscores its claim to becoming Europe’s leading one-stop pharma services provider in the field
of early stage drug development for the pharmaceutical industry with its third acquisition since 2011. The
integration of parts of the former Galderma R&D will add 80 employees to Nuvisan's existing 325 employees to
give 400+ employees in the Nuvisan group.
Related: CRO - analytical services
Is general: Yes